Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma Breuhahn K; Schirmacher PWorld J Gastroenterol 2008[Mar]; 14 (11): 1690-8Constitutive activation of the insulin-like growth factor (IGF)-signaling axis is frequently observed in human hepatocellular carcinoma (HCC). Especially the overexpression of the fetal growth factor IGF-II, IGF-I receptor (IGF-IR), and cytoplasmic downstream effectors such as insulin-receptor substrates (IRS) contribute to proliferation, anti-apoptosis, and invasive behavior. This review focuses on the relevant alterations in this signaling pathway and independent in vivo models that support the central role IGF-II signaling during HCC development and progression. Since this pathway has become the center of interest as a target for potential anti-cancer therapy in many types of malignancies, various experimental strategies have been developed, including neutralizing antibodies and selective receptor kinase inhibitors, with respect to the specific and efficient reduction of oncogenic IGF-II/IGF-IR-signaling.|*Signal Transduction/drug effects[MESH]|Animals[MESH]|Antibodies, Monoclonal/pharmacology[MESH]|Antineoplastic Agents/pharmacology[MESH]|Carcinoma, Hepatocellular/drug therapy/*metabolism/pathology[MESH]|Cell Transformation, Neoplastic/metabolism[MESH]|Humans[MESH]|Insulin-Like Growth Factor II/*metabolism[MESH]|Liver Neoplasms, Experimental/metabolism[MESH]|Liver Neoplasms/drug therapy/*metabolism/pathology[MESH]|Protein Kinase Inhibitors/pharmacology[MESH]|Receptors, Somatomedin/metabolism[MESH]|Up-Regulation[MESH] |